What the label insists on is rotation: a different spot every week.
Those points come from the FDA prescribing information and the Instructions for Use printed with it.1 The planner below turns "rotate with each dose" into a list of spots with dates. The rest of the page covers what the label says about each area, why it asks you to rotate, how common reactions at the site are, and which popular claims about "the best site" have nothing behind them.
Where should my next injection go?
Tap the spot you used last on the figure, enter the date of your next injection and choose which areas you use. The list gives a spot for each of the coming weeks.
Tap a point to mark your last site. The dark point is the next one. R and L are the person's right and left.
The app remembers every site you have used and shows the one that has rested longest.
Open the appOne way to follow the label's instruction to rotate. The label does not prescribe an order or a number of spots.
The plan goes round the spots in a fixed order, so the question "where did I inject last week?" always has an answer. With six spots, each one is used once every six weeks. The label asks for less than that. It only requires that two injections in a row do not go into the same spot. A longer cycle makes the rule easy to keep without thinking.
Where can Zepbound be injected?
The label names three areas, and treats one of them differently.1
| Area | Who can inject | What the label says |
|---|---|---|
| Abdomen (stomach area) | You, or another person | "under the skin of your stomach area (abdomen) or thighs" |
| Thigh | You, or another person | the same sentence |
| Back of the upper arm | Another person | "another person should inject in the back of the upper arm" |
The dosing section puts it in one line: "Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm." The Instructions for Use repeat it from the patient's side: you can inject your own stomach area or thighs, and "someone else can inject in your stomach area, thighs, or the back of the upper arms".1
The arm rule is practical. Reaching the back of your own upper arm with one hand while holding the skin and the pen steady is awkward, and an injection given at a bad angle may not go where it should. If nobody else gives your injections, the abdomen and the thighs are your areas, and they offer more than enough room to rotate.
Is one site better than the others?
Not as far as the drug is concerned. The label's pharmacology section states: "Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm."1 Exposure is the amount of drug that gets into the blood over time. The same section gives the share of an injected dose that reaches the blood as 80%, with no difference by site.
The label does not rank the areas, and it reports no trial that compared weight loss or side effects by injection site. Its tables give the trial results for everyone together, with no breakdown by site. So any claim that one area "works better" has no trial to stand on.
You will find specific numbers online, for example that the abdomen absorbs the drug a certain percentage faster than the thigh. The label contains no such figures, and its own statement points the other way. For a weekly drug with a half-life of about 5 days, a small difference in how fast one dose is absorbed would in any case be smoothed out: the level in the body is the sum of several weeks of doses.
That leaves the reasons that are real: where you can reach, where you can see what you are doing, and where an injection bothers you least. Those differ from person to person, and the label leaves the choice to you.
Why does the label ask me to rotate?
To protect the skin. The Instructions for Use give the reason in full: change the injection site "within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites".1 Repeated injections into one spot can change the tissue under the skin, and changed tissue is a poor place for the next injection.
The same passage lists where not to inject:
- where the skin has pits, is thickened or has lumps;
- where the skin is tender, bruised, scaly or hard;
- into scars or damaged skin.
How far to move is left open. The Medication Guide says: "You may use the same area of your body but be sure to choose a different injection site in that area. Do not use the same site for each injection."1 Staying on the abdomen every week is within the label, as long as the spot moves. Changing area every week is equally within it. The planner above treats four spots on the abdomen, two on the thighs and two on the arms as separate sites, which keeps each one out of use for weeks at a time.
How common are reactions at the injection site?
Less common than the stomach side effects, and more common than with a placebo injection. The label counts them across the two main trials.
Studies 1 and 2 pooled, up to 72 weeks of weekly injections. A reaction counted if it was reported at any time.
Reactions at the site were reported by 6 in 100 people on 5 mg and 8 in 100 on 10 and 15 mg, against 2 in 100 who injected placebo.1 The placebo figure matters: it shows that the needle and the injection itself account for part of the total, whatever is in the pen.
The label adds one finding about who gets them. Some people develop antibodies to tirzepatide during treatment. Among those who did, 11.3% had injection-site reactions. Among those who did not, 1%.1 A reaction that keeps coming back at different sites is therefore something to mention to your prescriber. It is more likely to be about how your body responds to the drug than about your technique.
The numbers behind the table
Table 1 of the label pools two trials, SURMOUNT-1 and SURMOUNT-2, each 72 weeks long. Together they put 630 people on 5 mg, 948 on 10 mg and 941 on 15 mg, with 958 on placebo: 2,519 people injecting Zepbound once a week, for up to 72 injections each. A rate of 6% on 5 mg is about 38 of 630 people. A rate of 8% is about 76 of 948 on 10 mg and 75 of 941 on 15 mg. On placebo, 2% is about 19 of 958.1
Two neighbouring rows of the same table help to read these figures. Allergic-type reactions of any kind were reported by 5 in 100 people on each dose and 3 in 100 on placebo. Hair loss, which has nothing to do with the injection site, was reported by 4 to 5 in 100. Reactions at the site were in the same range as these less common effects, and far below nausea, at 25 to 29 in 100.
Antibodies in numbers
Antibodies to the drug are common and, for most people, silent. In the two main weight-loss trials they were detected in 64.5% of people on Zepbound, 1,591 of 2,467.1 Most of those people never had a reaction at the site: 11.3% of them did. The figure to compare it with is 1% among people without antibodies. So antibodies raise the chance of a skin reaction about tenfold, from rare to occasional. The label does not ask for antibodies to be tested.
Put together with the placebo figure, the label describes three separate sources of a sore or red spot: the needle, which accounts for the 2 in 100 seen with placebo; the body's response to the drug, which is where antibodies come in; and repeated use of one place, which rotation prevents.
A skin reaction at the site is different from an allergic reaction of the whole body. The label lists swelling of the face, lips, tongue or throat, trouble breathing or swallowing, a severe rash or itching, fainting and a very rapid heartbeat as signs of a serious allergic reaction, and says to stop the drug and get medical help right away.1
What does the label say about the injection itself?
The steps differ by device, and each device comes with its own instructions. A few points are the same for all of them.1
Every injection
For the vial and the KwikPen the instructions add details that prevent the most common slips. The needle stays in the skin "for at least 5 seconds to make sure you have injected all of your dose". If there is a drop of blood afterwards, press the spot with gauze, and "do not rub the area". A new needle is used for every injection, and needles are not recapped.
For a vial, the Instructions for Use number the steps, and the last four are the injection itself.1
| Step | Instruction for the vial and syringe |
|---|---|
| 13 | Choose your injection site |
| 14 | Insert the needle into your skin |
| 15 | Push down on the plunger to inject your dose; keep the needle in for at least 5 seconds |
| 16 | Pull the needle out of your skin; if there is blood, press with gauze and do not rub |
The supplies listed for a vial injection are the vial, a syringe and needle, one alcohol swab, gauze and a sharps container. In the KwikPen instructions the alcohol swab has a named job: "Wipe the red inner seal with an alcohol swab" before a new needle goes on. Cleaning the skin is a question people often ask about. The numbered steps quoted here go from choosing the site straight to inserting the needle, so follow the leaflet for your own device and what you were shown in training.
Two rules are about sharing. A KwikPen holds four doses for one person, and the label carries a warning with its own section: never share it with anyone, even with a new needle, because of the risk of passing on an infection. And Zepbound is not mixed with any other medicine in the same syringe.
The label expects training before the first injection and again whenever the device changes. If your prescription moves from single-dose pens to vials or to the KwikPen, the steps are different, and the label asks for the new Instructions for Use to be read first.
Where exactly on the abdomen or thigh?
The prescribing information stops at the name of the area: "stomach area (abdomen)" and "thighs". It does not give distances or draw a zone. The leaflet that comes in the carton with your pen is the place to look for a picture of the area for your device, and it takes priority over any general description.
What the label does say applies everywhere: choose skin that is not tender, bruised, scaly, hard, scarred or damaged, and not a place with pits, thickening or lumps. On the abdomen that excludes a surgical scar. On the thigh it excludes a bruise from last month's injection. Within those limits, the abdomen offers the most room, which is why a rotation that never leaves it is still workable.
Does one site hurt less?
No trial measured it. The label has no data on pain by injection area, and its only relevant table counts reactions at the site without saying where on the body they occurred.
What you can do is find out for yourself in a way that gives an answer. Use each area in turn for a few weeks and note how each injection felt. Six entries are enough to see whether one area is consistently easier for you. That is a better guide than a general ranking, because the ranking does not exist.
Does the site change nausea or other side effects?
The label gives no reason to think so. Side effects such as nausea follow the amount of drug in the body, and the label reports that this amount is similar from the abdomen, the thigh and the arm. Its tables of side effects are not broken down by injection site, so there is no trial figure for "less nausea from the thigh" or any similar claim.
You may hear that a change of site helped someone. With side effects that fade on their own over the first weeks of each dose, a change made at the right moment will often seem to work. If you want to test it for yourself, the honest way is to log the site and the side effects for several weeks and look at the pattern, which is the kind of record the app keeps.
Are the sites the same for Mounjaro, Wegovy and Ozempic?
For Mounjaro, yes, word for word. It is the same drug in the same devices, and its label carries the same sentence about the abdomen, the thigh and another person injecting in the back of the upper arm.2
Wegovy names the same three areas with one difference: its instructions say you can inject "under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm" without requiring a second person for the arm. They add a warning: "Do not inject WEGOVY into a muscle (intramuscularly) or vein (intravenously)." The rotation rule is the same: "Change (rotate) your injection site with each injection. Do not use the same site for each injection."3
| Zepbound, Mounjaro | Wegovy | |
|---|---|---|
| Abdomen | Yes | Yes |
| Thigh | Yes | Yes |
| Upper arm | Back of the arm, by another person | Yes |
| Rotate | With each dose | With each injection |
| Same exposure from each area | Stated in the label | Stated in the label |
Does changing the site affect my schedule?
No. The dose, the day and the site are independent. A new site does not shift your weekly day, and the label's timing rules are counted from the time of the injection wherever it went. If a dose is late, it can be taken within 4 days of when it was due, into the next spot on your list. Our missed dose page checks that rule against your dates, and the dosing schedule shows how the dose rises while the rotation carries on underneath it.
What is the easiest way to keep track?
Write down the spot at the moment you inject. Memory is unreliable for something that happens once a week and takes ten seconds. A week later, "left or right?" is a guess for most people, and a guess defeats the purpose of rotating.
Three things make a useful record: the date, the dose and the spot. With those you can see at a glance which spot has rested longest, and you can connect a skin reaction to the place and the dose it followed. If a lump, a pit or a patch of thickened skin appears, the record shows how often that spot was used, and the label's instruction is to stop injecting there.
Short answers to common questions
Can I inject in the same area every week?
Yes, if the spot within the area changes. The Medication Guide says you may use the same area of your body but must choose a different injection site in it.
Can I inject my own arm?
The label says another person should inject in the back of the upper arm. For self-injection it names the abdomen and the thighs.
Does the thigh absorb the drug more slowly?
The label reports similar exposure from the abdomen, thigh and upper arm and gives no figures for a difference in speed.
I see a drop of blood after the injection. Is the dose lost?
No. The instructions say to press the spot with gauze and not to rub it.
How long should the needle stay in?
For the vial and the KwikPen, at least 5 seconds after the plunger is pushed. Single-dose pens have their own steps in the leaflet in the carton.
Is a small lump after an injection normal?
Reactions at the site were reported by 6 to 8 in 100 people in the trials. The label says not to inject where the skin has lumps, pits or thickening, and a lump that does not go away is worth showing to your prescriber.
Can I inject through a tattoo or stretch marks?
The label does not mention either. It rules out scars and damaged skin, and skin that is tender, bruised, scaly or hard.
I used the same spot two weeks in a row. Is that a problem?
Once is not what the rule is about. The risk the label describes comes from repeated use of one place. Move to the next spot and carry on.
Can a family member give all my injections?
Yes. Another person can inject in the abdomen, the thighs or the back of the upper arms, and the label expects whoever injects to be trained on the device.
Should the injection day change when the site does?
No. The weekly day stays the same. The site is the only thing that moves each week.
How many spots do I need in a rotation?
The label sets no number. Two spots used in turn already satisfy "a different site each week". More spots give each one longer to rest: with 4 a spot rests 3 weeks, with 6 it rests 5, with 8 it rests 7.
Does it matter which side of the body I use?
No. Left and right double the number of spots in a rotation, which is their only role.
How the planner works
The planner divides the label's three areas into eight spots: four on the abdomen, one on each thigh and one on the back of each upper arm. It goes round the spots you have chosen in a fixed order, starting after the one you tapped, and gives each a date one week after the last. The order is a convenience. The label requires only that the site changes with each dose.
The chart of reactions uses the row "Injection site reactions" of Table 1 in the label, which pools the two main trials. All statements about the areas, rotation and technique are quoted from the prescribing information, the Medication Guide and the Instructions for Use in the August 2026 revision.
Sources
- ZEPBOUND (tirzepatide) prescribing information, Medication Guide and Instructions for Use, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2.4, 5.6, 5.10, 6.1 and 12.3, Table 1. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information. Eli Lilly and Company; label text as published by the U.S. Food and Drug Administration, July 2026; section 2.2. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) prescribing information and Medication Guide, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2.1 and 12.3. accessdata.fda.gov
Related analyses
How long can Zepbound be out of the fridge? The label limits, checked for your pen
Missed a dose of Zepbound or Wegovy? The label rule, checked against your dates
Zepbound and birth control pills: the 4-week rule, with your dates
Zepbound dosing schedule: every step from 2.5 to 15 mg, with your dates
Log each injection with its site and the app picks the next one.
Open Dose Insider